title: Cardiac markers and risk stratification: an integrated approach.
abstract: Risk stratification of patients with acute coronary syndromes (ACS) is pivotal for correct allocation of health resources and for maximizing the benefit of available treatment modalities. However, clinical and electrocardiographic indicators of high risk lack sufficient sensitivity for the detection of major cardiac events. The complementary information provided by the measurement of different biomarkers is believed to be very useful. Specifically, elevations of cardiac troponin I (cTnI) and T (cTnT) are strongly associated with a high-risk profile both at short- and long-term. This has been definitely demonstrated in many studies as well as in cumulative meta-analysis. The role of different biomarkers, such as those reflecting activation of hemostasis and the presence of inflammation, is however less defined. At the moment, no study has prospectively evaluated these biomarkers in the whole spectrum of unselected patients with ACS. It is also unclear whether these biomarkers add independent prognostic value to the clinical and electrocardiographic indicators of adverse outcome and whether they offer additional information when compared to each other. The Early Prognostic Value of Biochemical Markers of Myocardial Damage, Activation of Hemostatic Mechanism and Inflammation in Acute Ischemic Syndromes (EMAI) study has been prospectively designed to solve these issues. In this study, we have evaluated the prognostic value of cTnI and cTnT, D-dimer, prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT) and C-reactive protein (CRP) in patients with ACS at the time of admission. We have enrolled in 31 Italian Coronary Care Units 1971 patients with rest anginal pain within 12 h from admission and electrocardiographic evidence of myocardial ischemia. Of these, 730 patients resulted to have ST-segment elevation myocardial infarction eligible for a reperfusion strategy and 1241, an acute coronary syndrome without persisting ST-segment elevation. Primary outcome measure of the study is the composite of death and non-fatal MI within 30 days from admission, which has occurred in 8.9% of the study population.
authors.affiliation: Cardiovascular Research Unit, Fondazione Sacco, Forlì, Italy. galvanim@tin.it
authors.forename: M
authors.initials: M
authors.lastname: Galvani
authors.forename: D
authors.initials: D
authors.lastname: Ferrini
authors.forename: F
authors.initials: F
authors.lastname: Ghezzi
authors.forename: F
authors.initials: F
authors.lastname: Ottani
mesh_terms: D000818:Animals; D015415:Biomarkers; D003327:Coronary Disease / Q000175:diagnosis / Q000378:metabolism; D004562:Electrocardiography; D006331:Heart Diseases / Q000175:diagnosis* / Q000378:metabolism; D006801:Humans; D018570:Risk Assessment
chemical_list: D015415:Biomarkers